The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial
Abstract
Purpose: In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus fluorouracil (FU), and leucovorin (IFL). Patients and Methods: Patients with metastatic colorectal cancer who progressed after IFL therapy were randomly assigned to bolus and infusional FU and leucovorin (LV5FU2), single-agent oxaliplatin, or the combination (FOLFOX4). This planned interim analysis evaluated objective response rate (RR), time to tumor progression (TTP), and alleviation of tumor-related symptoms (TRS) in an initial cohort of patients. Results: Between November 2000 and September 2001, 463 patients from 120 sites in North America were randomly assigned to treatment. FOLFOX4 proved superior to LV5FU2 in all measures of clinical efficacy. Objective RRs determined by an independent radiology panel were 9.9% for FOLFOX4 versus 0% for LV5FU2 (Fisher’s exact test, P < .0001). Median TTP was 4.6 months for FOLFOX4 versus 2.7 months for LV5FU2 (two-sided, stratified log-rank test, P < .0001). Relief of TRS occurred in 33% of patients treated with FOLFOX4 versus 12% of patients treated with LVFU2 (χ 2 test, P < .001). Single-agent oxaliplatin was not superior to LV5FU2 in any measure of efficacy. Patients treated with FOLFOX4 experienced a higher incidence of clinically significant toxicities than patients treated with LV5FU2, but these toxicities were predictable and did not result in a higher rate of treatment discontinuation or 60-day mortality rate. Conclusion: For patients with metastatic colorectal cancer, second-line treatment with FOLFOX4 is superior to treatment with LVFU2 in terms of RR, TTP, and relief of TRS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Self-citationde Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Self-citationRougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03085-2 · Cited by 992
Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., & Fojo, T. (1996) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)81490-6 · Cited by 615
Machover, D., Diaz-Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J.-J., Brienza, S., Itzhaki, M., Metzger, G., N'Daw, D., Vignoud, J., et al. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010489 · Cited by 434
Rothenberg, M. L., Meropol, N. J., Poplin, E. A., Van Cutsem, E., & Wadler, S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3801 · Cited by 425
Self-citationNordic Gastrointestinal Tumor Adjuvant Therapy Group (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.904 · Cited by 356
Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.
Sobrero, A. F., Aschele, C., & Bertino, J. R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.368 · Cited by 336
Maindrault-Goebel, F., Louvet, C., André, T., Carola, E., Lotz, J. P., Molitor, J. L., Garcia, M. L., Gilles-Amar, V, Izrael, V, Krulik, M., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00149-5 · Cited by 290
André, T., Bensmaine, M. A., Louvet, C., François, E., Lucas, V., Desseigne, F., Beerblock, K., Bouché, O., Carola, E., Merrouche, Y., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3560 · Cited by 277
Levi, F., Perpoint, B., Garufi, C., Focan, C., Chollet, P., Depres-Brummer, P., Zidani, R., Brienza, S., Itzhaki, M., Iacobelli, S., et al. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90073-o · Cited by 218
Borner, M. M., Dietrich, D., Stupp, R., Morant, R., Honegger, H., Wernli, M., Herrmann, R., Pestalozzi, B. C., Saletti, P., Hanselmann, S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.087 · Cited by 169
Maindrault‐Gœbel, F., de Gramont, A., Louvet, C., André, T., Carola, É., Mabro, M., Artru, P., Gilles-Amar, V., Lotz, J., Izrael, V., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00068-5 · Cited by 157
André, T., Louvet, C., Raymond, É., Tournigand, C., & de Gramont, A. (1998) · Annals of Oncology · doi:10.1023/a:1008475122124 · Cited by 124
Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer.
Bleiberg, H., & de Gramont, A. (1998) · PubMed · Cited by 102
Activity of oxaliplatin against human tumor colony-forming units.
Raymond, É., Lawrence, R., Izbicka, E., Faivre, S. J., & Hoff, D. D. V. (1998) · PubMed · Cited by 79
Nordin, K., Steel, J., Hoffman, K., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2046 · Cited by 71
Fischel, J., Étienne-Grimaldi, M.-C., Formento, P., & Milano, G. A. (1998) · PubMed · Cited by 62
Fischel, J.-L., Rostagno, P., Formento, P., Dubreuil, A., Etienne, M. C., & Milano, G. A. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1600 · Cited by 54
Mori, A., Bertoglio, S., Guglielmi, A., Aschele, C., Bolli, E., Tixi, L., Rosso, R., & Sobrero, A. F. (1993) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685339 · Cited by 50
Janinis, J., Papakostas, P., Samelis, G. F., Skarlos, D. V., Papagianopoulos, P., & Fountzilas, G. (2000) · Annals of Oncology · doi:10.1023/a:1008397109048 · Cited by 32
Chau, I., Webb, A., Cunningham, D., Hill, M. E., Waters, J. S., Norman, A. R., & Massey, A. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2036 · Cited by 23
Cited by
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
“• FOLFOX [62, 90] + Bmab [85, 91] • CapeOX (note 2) [92] + Bmab [85] ▪ SOX + Bmab ▪ FOLFOX + Cmab/Bmab”
InfluentialGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Metadata
- Authors
- Rothenberg, M. L., Oza, A. M., Bigelow, R. H., Berlin, J. D., Marshall, J. L., Ramanathan, R. K., Hart, L. L., Gupta, S., Garay, C. A., Burger, B. G., Le Bail, N., & Haller, D. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-06-01
- Volume
- 21
- Issue
- 11
- Pages
- 2059-2069
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2123133140
- Cited by
- 646
- References
- 25
- FWCI
- 27.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.